Zai Lab Limited ZLAB
26.86 USD +1.38 (+5.42%)
At closeNov 9, 2026, 4:00 PM EST
26.86 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
26.57 Day range 29.02
15.96 52-week range 29.02
- YTD
- +52.27%
- 1 year
- +22.65%
News
marketbeat.com Zai Lab Q3 Earnings Call Highlights Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate…
zacks.com Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Zai Lab Limited (ZLAB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
benzinga.com Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium In the Phase 1b/2 trial, zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, demonstrated clinically meaningful responses in patients with previously treated advanced…
benzinga.com Zai Lab Q3 2026 Earnings Call Transcript Zai Lab (NASDAQ:ZLAB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Zai Lab Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $108.208M Beat $105.825M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 33.33 percent decrease over losses of $(0.03) per…
businesswire.com Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026,…
benzinga.com Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3 At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of…
benzinga.com Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…
benzinga.com The Insider Report: The Leaders Have Taken Off Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and…
benzinga.com Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com Citigroup Maintains Buy on Zai Lab, Raises Price Target to $45 Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the price target from $44 to $45.
benzinga.com Zai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.06) by 666.67 percent. This is a 24.32 percent decrease over losses of $(0.37)…- benzinga.com Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas - NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need- U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for…
- benzinga.com Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas - European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies…
benzinga.com UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Monday.
benzinga.com The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, formerly ZL-1310) for Extrapulmonary Neuroendocrine Carcinomas Following Progression After Standard First-Line Therapy Zai Lab reported promising preliminary data from an ongoing registration-enabling multicenter, Phase 1b/2 clinical trial of zoci (NCT06885281) in patients with epNEC and other selected solid tumors…- benzinga.com Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $44 Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the price target from $47 to $44.
- benzinga.com Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.54) by 14.81 percent. This is a 2.22 percent decrease over losses of $(0.45) per…
- benzinga.com Zai Lab Announces Clinical Data Indicating Zoci, DLL3-Targeting ADC, Provides Rapid And Robust Intracranial Responses In Patients With Previously Treated ES-SCLC And Brain Metastases And Other NECs Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases;…
benzinga.com Boehringer Ingelheim, Zai Lab Collaborate Over Dual DLL3-Targeting Combination To Assess Safety, Tolerability Of Combining Obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-Cell Engager Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The- benzinga.com Zai Lab and Amgen Team Up to Test New Combo Treatment for Lung Cancer Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3…
benzinga.com JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $32 JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $39 to $32.- benzinga.com Zai Lab To Present Investigational Oncology Therapies To Be Presented Across Four Posters At American Association For Cancer Research Annual Meeting 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming…
- benzinga.com Cantor Fitzgerald Maintains Overweight on Zai Lab, Lowers Price Target to $37 Cantor Fitzgerald analyst Li Watsek maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $55 to $37.
- benzinga.com CORRECTION: Zai Lab Q4 EPADS $(0.46) Misses $(0.05) Estimate, Sales $127.597M Beat $124.472M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.05) by 838.78 percent. This is a 42.5 percent increase over losses of $(0.80)…
benzinga.com Zai Lab: Q4 Earnings Insights 
benzinga.com Zai Lab Q4 Earnings Summary & Key Takeaways 
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com An Overview of Zai Lab's Earnings - benzinga.com JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $39 JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $46 to $39.
benzinga.com Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter 
benzinga.com FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a pre-NDA meeting.
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Earnings Scheduled For August 7, 2025 
benzinga.com Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Earnings Scheduled For May 8, 2025 
benzinga.com Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday 
benzinga.com Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - benzinga.com Earnings Scheduled For February 27, 2025
benzinga.com Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - benzinga.com Earnings Scheduled For November 12, 2024
- benzinga.com Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- benzinga.com Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
- benzinga.com Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session.